Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission
Sponsor: Biovest International
Listed as NCT00091676, this PHASE3 trial focuses on Non-Hodgkins Lymphoma and remains ongoing. Sponsored by Biovest International, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Jan 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biovest International
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.